Attend World Bispecific to realize the next generation of bispecific drugs.
Over 3 days, 27 leading experts will share transferable insights to accelerate the development of your lead bispecific candidate, and ultimately see more in the clinic.
Focusing solely on bispecific development, this technical forum offers you an unrivaled wealth of scientific content. And with this, delivers you the tools for developing more clinically robust bispecific drugs.
Last year saw the ground-breaking approval of Blinatumomab for ALL. Reaching this landmark, and with an additional 30+ bispecifics currently in clinical development, we are on the cusp of these drugs coming of age. But, realizing their full potential is not without challenge, so now is the time to attend World Bispecific. Learn key lessons from your peers. Improve your clinical success.
Attend World Bispecific to:
Overcome specificity and stability challenges to develop the optimal bispecific with F-Star, Glenmark Pharmaceuticals and Ablynx.
Reduce production impurities by hearing of the latest chromatography technologies with insight from Eli Lilly.
Identify and validate synergistic targets for maximum effect with Barbara Ann Karmanos Cancer Institute.
Improve preclinical development to guarantee clinical efficacy with insight from Merrimack Pharmaceuticals, Merus and Regeneron Pharmaceuticals.
Develop constructs for solid tumors which have superior potency and extended half-life with Roche.
Critically review preclinical and early clinical development of bispecific programs at Amgen, Pfizer and AbbVie. Take home lessons learned to bypass avoidable mistakes and accelerate your development.
Confidently measure toxicity liability with preclinical PK, PD and safety evaluation insight from Genentech.
This is the definitive technical forum for anyone working on bispecifics. You will leave with sharp actionable insights to improve your clinical success.
Over 3 days, 27 leading experts will share transferable insights to accelerate the development of your lead bispecific candidate, and ultimately see more in the clinic.
Focusing solely on bispecific development, this technical forum offers you an unrivaled wealth of scientific content. And with this, delivers you the tools for developing more clinically robust bispecific drugs.
Last year saw the ground-breaking approval of Blinatumomab for ALL. Reaching this landmark, and with an additional 30+ bispecifics currently in clinical development, we are on the cusp of these drugs coming of age. But, realizing their full potential is not without challenge, so now is the time to attend World Bispecific. Learn key lessons from your peers. Improve your clinical success.
Attend World Bispecific to:
Overcome specificity and stability challenges to develop the optimal bispecific with F-Star, Glenmark Pharmaceuticals and Ablynx.
Reduce production impurities by hearing of the latest chromatography technologies with insight from Eli Lilly.
Identify and validate synergistic targets for maximum effect with Barbara Ann Karmanos Cancer Institute.
Improve preclinical development to guarantee clinical efficacy with insight from Merrimack Pharmaceuticals, Merus and Regeneron Pharmaceuticals.
Develop constructs for solid tumors which have superior potency and extended half-life with Roche.
Critically review preclinical and early clinical development of bispecific programs at Amgen, Pfizer and AbbVie. Take home lessons learned to bypass avoidable mistakes and accelerate your development.
Confidently measure toxicity liability with preclinical PK, PD and safety evaluation insight from Genentech.
This is the definitive technical forum for anyone working on bispecifics. You will leave with sharp actionable insights to improve your clinical success.
